Comerica Bank
LXRX icon

Comerica Bank’s Lexicon Pharmaceuticals LXRX Stock Holding History

Comerica Bank’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$140 Hold
122
– – ﹤0.01% 3680
2025
Q3 		$165 Hold
122
– – ﹤0.01% 3684
2025
Q2 		$115 Hold
122
– – ﹤0.01% 3666
2025
Q1 		$56 Hold
122
– – ﹤0.01% 3666
2024
Q4 		$90 Buy
+122
New +$147 ﹤0.01% 3651
2024
Q3 		– Sell
-122
Closed -$205 – 3728
2024
Q2 		$205 Hold
122
– – ﹤0.01% 3662
2024
Q1 		$293 Buy
+122
New +$262 ﹤0.01% 3701
2015
Q2 		– Sell
-3,254
Closed -$21K – 2076
2015
Q1 		$21K Sell
3,254
-3,253
-50% -$22.2K ﹤0.01% 2039
2014
Q4 		$42K Buy
6,507
+4,080
+168% +$32.9K ﹤0.01% 2038
2014
Q3 		$24K Buy
2,427
+281
+13% +$3K ﹤0.01% 2073
2014
Q2 		$24K Sell
2,146
-2,665
-55% -$28.6K ﹤0.01% 2107
2014
Q1 		$58K Buy
4,811
+485
+11% +$6.2K ﹤0.01% 2250
2013
Q4 		$54K Sell
4,326
-3,051
-41% -$48.5K ﹤0.01% 2231
2013
Q3 		$123K Buy
7,377
+612
+9% +$10.3K ﹤0.01% 2488
2013
Q2 		$103K Buy
+6,765
New +$103K ﹤0.01% 2197

Other funds holding LXRX

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CIBC Private Wealth Group
CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return

Comerica Bank's LXRX Position: Q4 2025 in Review

Comerica Bank held its Lexicon Pharmaceuticals (LXRX) position steady in Q4 2025 at 122 shares worth $140. The position accounts for ﹤0.01% of the portfolio, ranked #3680.

Comerica Bank first reported a position in LXRX in Q2 2013 and has held it in 15 quarters since. The position peaked at $123K in Q3 2013. 125 funds tracked by Wall St. Rank hold LXRX as of Q4 2025.

  • Comerica Bank held 122 shares of Lexicon Pharmaceuticals worth $140 as of Q4 2025.
  • Comerica Bank left its Lexicon Pharmaceuticals share count unchanged in Q4 2025.
  • Lexicon Pharmaceuticals made up ﹤0.01% of Comerica Bank's portfolio in Q4 2025, its #3680 holding.
  • Comerica Bank first reported a position in Lexicon Pharmaceuticals in Q2 2013 and has held it in 15 quarters since.
  • Comerica Bank's Lexicon Pharmaceuticals position peaked at $123K in Q3 2013.
  • 125 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q4 2025.

Based on Comerica Bank's 13F filing for Q4 2025, filed 29 Jan 2026.